Combined treatment of hepaCAM and pirarubicin inhibits the proliferation of bladder cancer BIU-87 cells

Abstract:

Objective：to investigate the effects of combination treatment of hepaCAM and pirarubicin（THP） on the proliferation of BI－U-87 cells. Methods：BIU-87 cells were designed as blank treatment group，adenovirus-GFP-hepaCAM treatment group（Ad-GFP-hepaCAM treatment group），THP treatment group，Ad-GFP-hepaCAM and THP combination treatment group. MTT was used to detect cell proliferation；cell cycle was evaluated by flow cytometry；the mRNA expressions of cyclinD1 and CDK2 were examined by re－al-time PCR. Cells that were designed as blank treatment group，Ad-GFP treatment group，Ad-GFP-hepaCAM treatment group were subcutaneously injected in nude mice. The volume of nude mice was evaluated. After 4 weeks，all mice were sacrificed，transplanted tumors were excised and tumor tissues were used to perform HE staining and immunohistochemistry was performed to examine hep－aCAM expression. Results：Ad-GFP-hepaCAM combined with THP exhibited more intense inhibitory effects on proliferation of BIU-87 cells than THP alone（F=2.702，P=0.000）. Meanwhile，the cell in G0/G1 was significantly increased（F=10.989，P=0.000） and mR－NA levels of cyclinD1 and CDK2 were significantly lowered in Ad-GFP-hepaCAM and THP combination treatment group than in THP group（F=5.4299，P=0.000）. In addition，the volume of tumors induced by hepaCAM-expression BIU-87 cells was significantly decreased compared with that of blank treatment group（F=12.587，P=0.000）. Conclusion：HepaCAM could enhance the inhibitory ef－fects of THP on the proliferation of bladder cancer BIU-87 cells.